Overview

Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

In this phase 2 study, we aim to evaluate the effects and safety of combined therapy using nab-paclitaxel and gemcitabine chemotherapy for patients after radical resection of Intrahepatic Cholangiocarcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel